Drug Trial Radar · NCT07260877
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Dec 3, 2025
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Ventus Therapeutics U.S., Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: * Take VENT-03 or a placebo for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks; * Visit the clinic once a month for checkups and tests.
Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Systemic Lupus Erythematosus
- SLE
- SLE (Systemic Lupus)
- CLE
Interventions
VENT-03Drug
VENT-03 is a tablet
PlaceboDrug
Placebo is a tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the effect of VENT-03 on the interferon gene signature in the skinTime frame: Baseline to End of Double-Blind Treatment (up to Day 28)
Locations
34 sites in 8 countries. Site status is shown where the registry gives one.
Investigative Site
Beverly Hills, California
Investigative Site
Clearwater, Florida
Investigative Site
DeBary, Florida
Investigative Site
Miami, Florida
Investigative Site
Tampa, Florida
Investigative Site
Indianapolis, Indiana
Investigative Site
Flint, Michigan
Investigative Site
Troy, Michigan
Investigative Site
Saint Joseph, Missouri
Investigative Site
Albuquerque, New Mexico
Investigative Site
Fairport, New York
Investigative Site
Memphis, Tennessee
Investigative Site
Allen, Texas
Investigative Site
Arlington, Texas
Investigative Site
Colleyville, Texas
Investigative Site
Haskovo, Bulgaria
Investigative Site
Plovdiv, Bulgaria
Investigative Site
Sofia, Bulgaria
Investigative Site
Paris, France
Investigative Site
Toulouse, France
Investigative Site
Tbilisi, Georgia
Investigative Site
Szeged, Hungary
Investigative Site
Bialystok, Poland
Investigative Site
Oświęcim, Poland
Investigative Site
Poznan, Poland
Investigative Site
Rzeszów, Poland
Investigative Site
Śląskie, Poland
Investigative Site
Warsaw, Poland
Investigative Site
Wroclaw, Poland
Investigative Site
Durban, South Africa
Investigative Site
Pretoria, South Africa
Investigative Site
Somerset West, South Africa
Investigative Site
Badajoz, Spain
Investigative Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.